35.71 
0.03(0.08%) 9:44AM EDT - Nasdaq Real Time Price
| Prev Close: | 35.74 |
|---|
| Open: | N/A |
|---|
| Bid: | 35.37 x 900 |
|---|
| Ask: | 35.83 x 100 |
|---|
| 1y Target Est: | 30.05 |
|---|
| Beta: | 0.6 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 35.62 - 35.81 |
|---|
| 52wk Range: | 28.62 - 37.78 |
|---|
| Volume: | 7,408 |
|---|
| Avg Vol (3m): | 1,645,220 |
|---|
| Market Cap: | 5.91B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.44 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- South Korea's Celltrion sale seen slow-going as sceptics emergeat Reuters(Tue, May 14)
- Hospira's former chief scientific officer returnsAP(Tue, May 14)
- Markman Hearing A Likely Clearing Event For Cubist - Decision Any Dayat Seeking Alpha(Tue, May 14)
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Dataat TheStreet(Tue, May 14)
- Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific OfficerPR Newswire(Tue, May 14)
- HOSPIRA INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 14)
- Hospira Inc. (HSP): Today's Featured Health Care Laggardat TheStreet(Mon, May 13)
- Stocks to Watch: Theravance, Endo Health, Perion Networkat The Wall Street Journal(Mon, May 13)
- [$$] Where European Investors Look for Valueat Barrons.com(Sat, May 11)
- Hospira Becomes #24 Most Shorted S&P 500 Component, Replacing Leggett & Plattat TheStreet(Fri, May 10)
- ICU Seen Extending Record With 21% Deal Premium: Real M&Aat Bloomberg(Fri, May 10)
- HOSPIRA INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 10)
- Rambus, Shire, Hospira, Viacom: Intellectual Propertyat Bloomberg(Fri, May 10)
- Hospira Sues B. Braun Over Infusion-Pump System Patentsat Bloomberg(Thu, May 9)
- ICU Said to Explore Sale That May Fetch $1 Billionat Bloomberg(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | 17.27 |
|---|
| P/S (ttm): | 1.47 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.03 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.51 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | 2.48 |
|---|
Business Summary
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drug...
View More